MedTrace Logo

Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients

NCT04593654 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 257

Last updated 2023-05-31

No results posted yet for this study

Summary

The aim of the study is to associate dose of thromboprophylaxis with outcome in critically ill COVID-19 patients. This will be done by associating dose of thromboprophylaxis with 28-day mortality, survival outside ICU, thromboembolic event and bleeding complications.This was done in our earlier study for patients admitted in March and April (Clinicaltrials.gov NCT04412304 June 2 2020) but now we will include the patients admitted in May, June and half of July and we will ad the outcome of 90-day mortality.

Conditions

  • Covid19
  • Thromboembolism

Interventions

DRUG

Dose of tinzaparin or dalteparin

The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU

Sponsors & Collaborators

Principal Investigators

  • Sandra Jonmarker, MD · Karolinska Institutet

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2020-08-15
Completion
2020-10-15

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04593654 on ClinicalTrials.gov